Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients

Michaela G. Cuneo, Angela Szeto, Andrew Schrepf, Ellen M. Kinner, Benjamin I. Schachner, Raisa Ahmed, Premal H. Thaker, Michael Goodheart, David Bender, Steve W. Cole, Philip M. McCabe, Anil K. Sood, Susan K. Lutgendorf, Armando J. Mendez

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. The purpose of this investigation was to examine relationships between endogenous oxytocin, tumor-associated inflammation (interleukin-6), and survival in advanced epithelial ovarian cancer patients. Methods: Tumor microenvironment (ascites) and plasma oxytocin levels were analyzed via ELISA on extracted samples obtained from 79 patients. In vitro models were used to characterize oxytocin and oxytocin receptor expression in four ovarian cancer cell lines and to investigate direct anti-inflammatory effects of oxytocin on tumor cell secretion of interleukin-6. High and variable levels of oxytocin were observed in ascites, up to 200 times greater than in plasma. Higher levels of ascites oxytocin were associated with lower levels of systemic and tumor-associated interleukin-6, an inflammatory cytokine implicated in ovarian tumor progression. Oxytocin also attenuated interleukin-6 secretion from multiple ovarian tumor cell lines in vitro. Higher levels of ascites oxytocin were associated with a significant survival advantage and statistical mediation analyses suggested this effect was partially mediated by interleukin-6. Conclusions: These data identify a previously unacknowledged hormone in the ovarian tumor microenvironment and provide initial evidence that oxytocin has protective effects in ovarian cancer via anti-inflammatory mechanisms. Future studies should examine the therapeutic utility of oxytocin.

Original languageEnglish (US)
Pages (from-to)244-251
Number of pages8
JournalPsychoneuroendocrinology
Volume106
DOIs
StatePublished - Aug 2019

Keywords

  • Ascites
  • Ovarian neoplasms
  • Oxytocin
  • Tumor microenvironment
  • interleukin-6

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Cuneo, M. G., Szeto, A., Schrepf, A., Kinner, E. M., Schachner, B. I., Ahmed, R., Thaker, P. H., Goodheart, M., Bender, D., Cole, S. W., McCabe, P. M., Sood, A. K., Lutgendorf, S. K., & Mendez, A. J. (2019). Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology, 106, 244-251. https://doi.org/10.1016/j.psyneuen.2019.04.007